Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcomi...
D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $12 price ...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and mai...
D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $12 price ...
CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(0.23) per share which missed the analyst consensus estim...
